Comparative Pharmacology
Head-to-head clinical analysis: EPLERENONE versus PLENAXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPLERENONE versus PLENAXIS.
EPLERENONE vs PLENAXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective aldosterone receptor antagonist (mineralocorticoid receptor antagonist). Binds to the mineralocorticoid receptor, blocking the effects of aldosterone, leading to decreased sodium reabsorption and potassium excretion in the kidney.
Selective androgen receptor modulator (SARM); binds to androgen receptors with high affinity, activating anabolic signaling pathways in muscle and bone with reduced androgenic effects on prostate and skin.
50 mg orally once daily, may increase to 50 mg twice daily after 4 weeks if tolerated; maximum 100 mg daily.
Initial: 10 mg orally once daily, titrated to blood pressure and heart rate response; maintenance: 20-80 mg daily in 1-2 divided doses.
None Documented
None Documented
Clinical Note
moderateEplerenone + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Acetyldigitoxin
Terminal elimination half-life is approximately 4 to 6 hours; in patients with heart failure or renal impairment, half-life may be prolonged (up to 8-12 hours). The short half-life supports twice-daily dosing.
Terminal elimination half-life is approximately 24 hours in healthy adults; clinically significant accumulation occurs in renal impairment (CrCl <30 mL/min) with half-life prolonged to 40-60 hours.
Approximately 67% of an oral dose is excreted in urine as metabolites (primarily inactive glucuronide conjugates) and approximately 32% in feces via biliary elimination; less than 5% of the dose is excreted unchanged in urine.
Renal: 70% as unchanged drug; fecal: 10% as metabolites; biliary: 5% as unchanged drug and metabolites.
Category C
Category C
Aldosterone Antagonist
Aldosterone Antagonist
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Eplerenone."